SLC9A2 and colorectal carcinoma: Given that Ruxolitinib has been reported to modulate melanoma cell-intrinsic resistance to anti-PD-1 [28], we wondered whether Ruxolitinib could mimic the function of SLC9A2 by inhibiting the STAT3 signaling pathway, thereby reversing immunotherapy resistance in CRC.